Juvenile Huntington's disease (onset <20 years), also known as the Westphal variant, presents with distinct neuropathology compared to adult-onset HD, featuring prominent cortical involvement, early rigidity, and seizures.
Juvenile HD accounts for approximately 5-10% of all Huntington's disease cases and is characterized by:
- Age of onset before 20 years
- CAG repeat expansions typically >60 (often 80-120)
- Predominantrigidity (Westphal variant) rather than chorea
- Rapid disease progression
- Prominent cortical and cerebellar pathology
| CAG Repeats |
Age of Onset |
Phenotype |
| 40-50 |
Adult (30-50y) |
Classic chorea |
| 51-60 |
Early adult (20-30y) |
Mixed features |
| 61-80 |
Juvenile (<20y) |
Rigidity predominant |
| >80 |
Childhood/infancy |
Severe, rapid |
- Paternal transmission bias (imprinting effects)
- Founder mutations in certain populations
- Meiotic instability in paternal germline
- Layer III Pyramidal Neurons: Severe loss, contributes to dementia
- Layer V Projection Neurons: Corticostriatal pathway disruption
- White Matter: Extensive demyelination, corticospinal tract involvement
- Synaptic Loss: Early pruning of corticocortical connections
- Medium Spiny Neurons: Early and severe loss
- Indirect Pathway: More vulnerable than direct pathway
- Matrix vs Striosome: Differential vulnerability
- Diffuse Involvement: Less focal than adult cases
- Purkinje Cell Loss: Contributes to ataxia
- Granule Cell Degeneration: Motor coordination deficits
- Deep Nuclei Involvement: Extracted cerebellar output disruption
- Climbing Fiber Inputs: Synaptic alterations
- Thalamus: Relay nucleus degeneration
- Hypothalamus: Neuroendocrine dysregulation
- Brainstem Nuclei: Cranial nerve involvement
- Substantia Nigra: Pars reticulata changes
- Protein Aggregation: Nuclear and cytoplasmic inclusions
- Transcriptional Dysregulation: Broad gene expression changes
- Mitochondrial Dysfunction: Energy metabolism impairment
- Autophagy Defects: Protein clearance disruption
- Neurogenesis Alterations: Neural progenitor cell effects
- Migration Abnormalities: Cortical patterning changes
- Synaptogenesis: Impaired circuit formation
- Myelination: Oligodendrocyte dysfunction
- Glutamate Receptor Hyperactivation: NMDA/AMPA overactivation
- Calcium Dysregulation: Intracellular calcium overload
- Metabolic Stress: Energy failure
- Oxidative Damage: ROS accumulation
- Rigidity: Bradykinesia, dystonia, parkinsonism
- Seizures: Myoclonic, generalized (50% of cases)
- Ataxia: Cerebellar signs prominent
- Chorea: Less prominent than adults (may be absent)
- Rapid Progression: Fast executive dysfunction
- Developmental Regression: Loss of acquired skills
- Language Regression: Speech deterioration
- IQ Decline: Progressive intellectual disability
- Behavioral Changes: Irritability, aggression
- Psychosis: Early-onset psychotic features
- Anxiety: Generalized anxiety disorder
- Depression: Suicidal ideation risk
- Growth Retardation: Delayed puberty
- Bone Density: Osteopenia/osteoporosis
- Cardiac Effects: Cardiomyopathy in some cases
- Weight Loss: Cachexia
- HTT-Lowering: Antisense oligonucleotides (ASOs)
- Mutant Huntingtin Stabilization: Small molecule inhibitors
- Autophagy Enhancement: mTOR-independent pathways
- Gene Editing: CRISPR approaches (preclinical)
- Tetrabenazine: For chorea when present
- Dopamine Modulators: For rigidity/dystonia
- Antiepileptic Drugs: For seizures
- Antipsychotics: For behavioral symptoms
- Physical Therapy: Maintain mobility
- Speech Therapy: Communication support
- Nutritional Support: Prevent cachexia
- Psychiatric Care: Mental health management
- Neurofilament Light Chain: Blood/CSF marker
- MRI Volumetrics: Regional brain atrophy
- FDG-PET: Metabolic changes
- Transcranial Ultrasound: Iron deposition
- ASO Trials: Multiple Phase 1/2 trials completed
- Small Molecule Modulators: HTT aggregators
- Cell Therapy: Stem cell approaches
- Neuroprotective Agents: CoQ10, creatine
- Juvenile HD neuropathology (2022)
- HD age of onset correlates (2021)
- Juvenile HD clinical features (2023)
- CAG repeat expansion mechanisms (2020)
- HTT-lowering therapies (2024)